文献速递乳腺癌

IMpassion130最终总生存分析:阿替利珠单抗联合白蛋白紫杉醇一线治疗晚期三阴性乳腺癌

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
PubMed 文献 · Ann Oncol · 2021-07-01

IMpassion130研究最终总生存分析显示,在不可手术局部晚期或转移性三阴性乳腺癌患者中,阿替利珠单抗联合白蛋白紫杉醇(A+nP)对比安慰剂联合白蛋白紫杉醇(P+nP)在ITT人群的中位OS为21.0个月 vs 18.7个月(分层HR 0.87,95%CI 0.75-1.02,P=0.077),未达统计学显著。探索性分析显示PD-L1 IC阳性人群的中位OS为25.4个月 vs 17.9个月(分层HR 0.67,95%CI 0.53-0.86)。安全性与此前分析一致。

要点

  • ITT人群OS获益未达统计学显著,中位OS 21.0 vs 18.7个月,HR 0.87。
  • PD-L1 IC阳性人群探索性分析显示临床有意义的OS获益,中位25.4 vs 17.9个月,HR 0.67。
  • 安全性与此前分析一致,免疫相关特别关注不良事件发生率A+nP组58.7% vs P+nP组41.6%。

核心结论

  • 尽管ITT人群OS获益未达统计学显著,PD-L1 IC阳性患者中A+nP观察到临床有意义的OS获益,与此前中期分析一致。
  • 该联合方案在更长随访中保持安全可耐受。

研究设计与样本

  • 随机对照III期研究IMpassion130,每臂451例患者,随机接受nP 100 mg/m2(28天周期第1、8、15天)联合阿替利珠单抗840 mg(第1、15天)或安慰剂(第1、15天),直至进展或不可接受毒性。
  • 共同主要终点为PFS(ITT和PD-L1 IC阳性人群)和OS(先在ITT人群分层检验,若显著再在PD-L1 IC阳性人群检验)。
  • 最终OS分析截止时,666例(73.8%)死亡,中位随访18.8个月(IQR 8.9-34.7个月)。

主要发现

  • ITT人群:A+nP组中位OS 21.0个月(95%CI 19.0-23.4),P+nP组18.7个月(95%CI 16.9-20.8),分层HR 0.87(95%CI 0.75-1.02,P=0.077)。
  • PD-L1 IC阳性人群探索性分析:A+nP组(n=185)中位OS 25.4个月(95%CI 19.6-30.7),P+nP组(n=184)17.9个月(95%CI 13.6-20.3),分层HR 0.67(95%CI 0.53-0.86)。
  • 安全性与此前分析一致;免疫相关特别关注不良事件在A+nP组和P+nP组分别为58.7%和41.6%。

临床怎么用

  • 对于PD-L1 IC阳性的不可手术局部晚期或转移性三阴性乳腺癌患者,一线可考虑阿替利珠单抗联合白蛋白紫杉醇治疗。
  • 治疗过程中需关注免疫相关特别关注不良事件,其发生率在联合组更高。

局限性

  • ITT人群OS获益未达统计学显著,PD-L1 IC阳性人群的OS分析为探索性,未进行正式检验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines recommend atezolizumab plus nab-paclitaxel (A + nP) for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer expressing programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (IC), based on IMpassion130. We report the final overall survival (OS) and safety of that study as per the prespecified analysis plan. PATIENTS AND METHODS: Patients were randomized to nP 100 mg/m2 (days 1, 8, and 15 of a 28-day cycle) with atezolizumab 840 mg (A + nP) or placebo (P + nP; days 1 and 15), until progression or unacceptable toxicity. Coprimary endpoints were progression-free survival [intention-to-treat (ITT) and PD-L1 IC-positive populations] and OS (tested hierarchically in the ITT population and, if significant, in the PD-L1 IC-positive population). RESULTS: Each arm comprised 451 patients; 666 (73.8%) had died by the final OS analysis cut-off (median follow-up, 18.8 months; interquartile range, 8.9-34.7 months). Median OS in the ITT population was 21.0 months [95% confidence interval (CI), 19.0-23.4 months] with A + nP, and 18.7 months (95% CI, 16.9-20.8 months) with P + nP [stratified hazard ratio (HR), 0.87; 95% CI, 0.75-1.02; P = 0.077]. Exploratory analysis in the PD-L1 IC-positive population showed a median OS of 25.4 months (95% CI, 19.6-30.7 months) with A + nP (n = 185) and 17.9 months (95% CI, 13.6-20.3 months) with P + nP (n = 184; stratified HR, 0.67; 95% CI, 0.53-0.86). Safety outcomes were consistent with previous analyses and the known toxicity profiles of each agent. Immune-mediated adverse events of special interest were reported in 58.7% and 41.6% of patients treated with A + nP and P + nP, respectively. CONCLUSION: Although the OS benefit in the ITT population was not statistically significant, precluding formal testing, clinically meaningful OS benefit was observed with A + nP in PD-L1 IC-positive patients, consistent with prior interim analyses. This combination remained safe and tolerable with longer follow-up.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021. PMID: 34272041. doi:10.1016/j.annonc.2021.05.355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。